Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Jul 29, 2011

Premium

Proteome Sciences has appointed Glenn Barney vice president of business development in North America.

Previously, Barney was VP of business development for NextGen Sciences. He has also held senior positions at Decision Biomarkers and PerkinElmer.


Dario Alessi has been appointed director of the Medical Research Council's Protein Phosphorylation Unit at the University of Dundee, a research group dedicated to the study of protein phosphorylation.

Alessi is currently deputy director of the unit as well as a professor of signal transduction in the College of Life Sciences at the University of Dundee. In 2005 he was awarded the EMBO Gold Medal, a research prize for life scientists under the age of 40, and was elected a fellow of the Royal Society in 2008.

Alessi will succeed the current director Philip Cohen, who will step down in April 2012.


BG Medicine has appointed former BioMérieux CEO Stephane Bancel to serve as chairman of its board of directors.

Bancel will replace Noubar Afeyan, a company founder and chairman of the board since the company's inception as well as CEO and managing partner of Flagship Ventures. Afeyan will continue to serve on the firm's board.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more